Use of a false recognition paradigm in an Alzheimer's disease clinical trial: a pilot study

Am J Alzheimers Dis Other Demen. 2002 Mar-Apr;17(2):93-100. doi: 10.1177/153331750201700204.

Abstract

We report the first use of a false recognition memory test in a clinical trial of patients with Alzheimer's disease (AD). Tests of false recognition allow measurement of two components of memory: the specific details of a prior encounter with a particular item (item-specific recollection) and the general meaning, idea, or gist conveyed by a collection of items (gist memory). We used a false recognition paradigm with categorized pictures to study the effects of an experimental medication in patients with AD. Because medications to treat AD may preferentially improve gist memory or item-specific recollection, use of this type of paradigm may improve sensitivity for detection of drug effects more than standard memory tests.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / psychology
  • Aminobenzoates*
  • Attention / drug effects*
  • Concept Formation / drug effects*
  • Double-Blind Method
  • Female
  • Humans
  • Hypoxanthines*
  • Male
  • Mental Recall / drug effects*
  • Neuropsychological Tests
  • Nootropic Agents / adverse effects
  • Nootropic Agents / therapeutic use*
  • Pattern Recognition, Visual / drug effects*
  • Pilot Projects
  • Purines*

Substances

  • Aminobenzoates
  • Hypoxanthines
  • Nootropic Agents
  • Purines
  • 4-((3-(1,6-dihyro-6-oxo-9H-purin-9-yl)-1-oxopropyl)amino)benzoic acid